SEDANS Stock Overview
A medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sedana Medical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 25.28 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 0.22 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 41.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| SEDANS | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.6% |
| 1Y | n/a | -10.7% | 4.6% |
Return vs Industry: Insufficient data to determine how SEDANS performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how SEDANS performed against the UK Market.
Price Volatility
| SEDANS volatility | |
|---|---|
| SEDANS Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: SEDANS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SEDANS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 81 | Johannes Doll | www.sedanamedical.com |
Sedana Medical AB (publ), a medtech and pharmaceutical company, develops, manufactures, and sells medical devices and pharmaceutical products in Sweden, Germany, and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-S, which are disposable medical devices that enable the administration of volatile anaesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; and Sedaconda (Isoflurane) for sedation of mechanically ventilated adult patients during intensive care, as well as AnaConDa, a medical device enabling administration of inhaled anaesthetics. It also provides FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; Scavenging tube, a one piece pre-connected tube designed to channel anaesthetic waste gas from the ventilator exhaust port and the gas monitor exhaust port to the FlurAbsorb filter; FlurAbsorb mount to hold the FlurAbsorb during scavenging of anesthetic gas; FlurAbsorb-S mount to hold the FlurAbsorb-S during scavenging of anesthetic gas; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and Mindray exhaust connector, which enables to connect the exhaust of the ventilator to an active or passive scavenging system.
Sedana Medical AB (publ) Fundamentals Summary
| SEDANS fundamental statistics | |
|---|---|
| Market cap | SEK 2.31b |
| Earnings (TTM) | -SEK 41.47m |
| Revenue (TTM) | SEK 168.68m |
13.7x
P/S Ratio-55.7x
P/E RatioIs SEDANS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEDANS income statement (TTM) | |
|---|---|
| Revenue | SEK 168.68m |
| Cost of Revenue | SEK 50.06m |
| Gross Profit | SEK 118.62m |
| Other Expenses | SEK 160.09m |
| Earnings | -SEK 41.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 24, 2024
| Earnings per share (EPS) | -0.42 |
| Gross Margin | 70.32% |
| Net Profit Margin | -24.59% |
| Debt/Equity Ratio | 0% |
How did SEDANS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/14 23:42 |
| End of Day Share Price | 2024/06/17 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sedana Medical AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Östling | Pareto Securities |
| Filip Wiberg | Pareto Securities |
| Oscar Bergman | Redeye |